Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | HCK | P08631 | 3/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173927 | 0.86 | CDK8 (0.41) | MAPK14MAPK12MAPK13MAPK11JAK2 | |
| SCHEMBL3187950 | 0.81 | CDK8 (0.50) | MAPK14MAPK12MAPK13MAPK11JAK2 | |
| SCHEMBL3169111 | 0.81 | MAPK14 (0.50) | MAPK14MAPK12MAPK13MAPK11JAK2 | |
| SCHEMBL3179866 | 0.81 | CDK8 (0.39) | MAPK14MAPK12MAPK13MAPK11JAK2 | |
| SCHEMBL3188140 | 0.79 | CDK8 (0.40) | MAPK14MAPK12MAPK13MAPK11JAK2 | |
| SCHEMBL3179274 | 0.79 | CDK8 (0.43) | MAPK14MAPK12MAPK13MAPK11JAK2 | |
| SCHEMBL3190573 | 0.78 | MAPK14 (0.45) | MAPK14MAPK12MAPK13MAPK11JAK2 | |
| SCHEMBL4420313 | 0.77 | MAPK14 (0.48) | MAPK14MAPK13JAK2 | |
| SCHEMBL3176393 | 0.77 | MAPK14 (0.51) | MAPK14MAPK12MAPK13MAPK11JAK2 | |
| SCHEMBL3187903 | 0.77 | MAPK14 (0.48) | MAPK14MAPK12MAPK13MAPK11JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1970375-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | UROD, UTS2R, SLC14A1 | MAPK14 500/4885MAPK12 1129/4885MAPK13 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.